Johnson & Johnson Says FDA OKs ICOTYDE, First Oral IL-23 Receptor Antagonist For Plaque Psoriasis

AI Briefing

• – Johnson & Johnson's ICOTYDE becomes first oral IL-23 receptor antagonist for plaque psoriasis; FDA approval for treatment of moderate-to-severe psoriasis; ICOTYDE to be marketed by Janssen Biotech